1
|
Vrielink H, Le Poole K, Stegmayr B, Kielstein J, Berlin G, Ilhan O, Seval GC, Prophet H, Aandahl A, Deeren D, Bojanic I, Blaha M, Lanska M, Gasova Z, Bhuiyan-Ludvikova Z, Blahutova S, Hrdlickova R, Audzijoniene J, Griskevicius A, Glatt T, Strineholm V, Ott M, Nilsson T, Newman E, Derfler K, Witt V, Toss F. The world apheresis association registry, 2023 update. Transfus Apher Sci 2023; 62:103831. [PMID: 37827962 DOI: 10.1016/j.transci.2023.103831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2023]
Abstract
The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs). MATERIAL AND METHODS: The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org RESULTS: Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018-2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0-94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%). CONCLUSION: The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.
Collapse
Affiliation(s)
- Hans Vrielink
- Unit of Transfusion medicine of Sanquin Blood Supply, Sanquin Blood Supply Foundation in Amsterdam, the Netherlands
| | - Kaatje Le Poole
- Unit of Transfusion medicine of Sanquin Blood Supply, Sanquin Blood Supply Foundation in Amsterdam, the Netherlands
| | - Bernd Stegmayr
- Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
| | - Jan Kielstein
- Academic Teaching Hospital Braunschweig, Medical Clinic V - Nephrology, Rheumatology, Blood Purification, Germany
| | - Gösta Berlin
- Department of Clinical Immunology and Transfusion Medicine, and Department of Biochemical and Clinical Sciences, Linköping University, Linköping, Sweden
| | - Osman Ilhan
- Department Haematology, University Hospital, Ankara, Turkey
| | | | | | - Astrid Aandahl
- Dep of Immunology and Transfusion Medicine, Akershus University Hospital, Lorenskog, Norway
| | | | - Ines Bojanic
- Clinical Department of Transfusion Medicine and Transplantation Biology, University Hospital Centre Zagreb, Croatia
| | - Milan Blaha
- IV. Internal Hematological Klinik, Fakultni Nemocnice, Hradec Králové, Czech Republic
| | - Miriam Lanska
- IV. Internal Hematological Klinik, Fakultni Nemocnice, Hradec Králové, Czech Republic
| | - Zdenka Gasova
- Apheresis Department, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
| | | | - Sarka Blahutova
- Blood Centre, University Hospital Ostrava, Ostrava, Czech Republic
| | | | - Judita Audzijoniene
- Therapeutic apheresis unit, Vilnius university hospital Santariskiu clinics, Vilnius, Lithuania
| | - Antanas Griskevicius
- Therapeutic apheresis unit, Vilnius university hospital Santariskiu clinics, Vilnius, Lithuania
| | - Tanya Glatt
- South African National Blood Service, Johannesburg, South Africa
| | | | - Michael Ott
- Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
| | - Thomas Nilsson
- Department of Nephrology, University Hospital, Uppsala, Sweden
| | - Elizabeth Newman
- Bone Marrow Transplant & Apheresis, Apheresis & Cell Therapies Unit, Concord Repatriation General Hospital, Concord, NSW, Australia
| | - Kurt Derfler
- The Institute for the Diagnosis and Therapy of Atherosclerosis and Fat Metabolism Disorders, Athos, Vienna, Austria
| | - Volker Witt
- St. Anna Kinderspital, University Hospital, Vienna, Austria
| | - Fredrik Toss
- Department of Clinical Microbiology, Division of Clinical Immunology, Umeå University, Umeå, Sweden
| |
Collapse
|
2
|
Stegmayr B, Newman E, Witt V, Derfler K, Leitner G, Eloot S, Dhondt A, Deeren D, Ptak J, Blaha M, Lanska M, Gasova Z, Bhuiyan-Ludvikova Z, Hrdlickova R, Ramlow W, Prophet H, Kielstein JT, Liumbruno G, Mori E, Griskevicius A, Audzijoniene J, Vrielink H, Rombout-Sestrienkova E, Aandahl A, Sikole A, Tomaz J, Lalic K, Bojanic I, Strineholm V, Brink B, Berlin G, Dykes J, Nilsson T, Eich T, Hadimeri H, Welander G, Ortega Sanchez S, Ilhan O, Poole C. Using the World Apheresis Association Registry Helps to Improve the Treatment Quality of Therapeutic Apheresis. Transfus Med Hemother 2021; 48:234-239. [PMID: 34539317 DOI: 10.1159/000513123] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Accepted: 04/07/2020] [Indexed: 01/20/2023] Open
Abstract
Therapeutic apheresis (TA) is prescribed to patients that suffer from a severe progressive disease that is not sufficiently treated by conventional medications. A way to gain more knowledge about this treatment is usually by the local analysis of data. However, the use of large quality assessment registries enables analyses of even rare findings. Here, we report some of the recent data from the World Apheresis Association (WAA) registry. Data from >104,000 procedures were documented, and TA was performed on >15,000 patients. The main indication for TA was the collection of autologous stem cells (45% of patients) as part of therapy for therapy. Collection of stem cells from donors for allogeneic transplantation was performed in 11% of patients. Patients with indications such as neurological diseases underwent plasma exchange (28%). Extracorporeal photochemotherapy, lipid apheresis, and antibody removal were other indications. Side effects recorded in the registry have decreased significantly over the years, with approximately only 10/10,000 procedures being interrupted for medical reasons. Conclusion Collection of data from TA procedures within a multinational and multicenter concept facilitates the improvement of treatment by enabling the analysis of and feedback on indications, procedures, effects, and side effects.
Collapse
Affiliation(s)
- Bernd Stegmayr
- Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
| | - Elizabeth Newman
- Bone Marrow Transplant and Apheresis, Concord, New South Wales, Australia
| | - Volker Witt
- St. Anna, Pediatric Department, Vienna, Austria
| | | | - Gerda Leitner
- Apheresis Unit, Haematological, AKH, Vienna, Austria
| | - Sunny Eloot
- Department of Nephrology, University Hospital, Ghent, Belgium
| | | | - Dries Deeren
- Department of Hematology, AZ Delta, Roeselare, Belgium
| | - Jan Ptak
- Transfusion Medicine, Frydek-Mistek, Czechia
| | - Milan Blaha
- Hemapheretic Center of the 3rd Department of Medicine, Medical Faculty and University Hospital, Hradec Kralove, Czechia
| | - Mirka Lanska
- Hemapheretic Center of the 3rd Department of Medicine, Medical Faculty and University Hospital, Hradec Kralove, Czechia
| | - Zdenka Gasova
- Institute of Hematology and Blood Transfusion, Prague, Czechia
| | | | | | | | | | - Jan T Kielstein
- Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital, Braunschweig, Germany
| | | | | | | | | | | | | | - Astrid Aandahl
- Center for Immunology and Transfusion, Akers University Hospital, Loerenskog, Norway
| | - Aleksandar Sikole
- Department of Nephrology, University Hospital, Skopje, North Macedonia
| | - Jorge Tomaz
- Apheresis Unit, Coimbra University Hospital, Coimbra, Portugal
| | - Katarina Lalic
- Institute for Endocrinology, University Hospital, Belgrade, Serbia
| | - Ines Bojanic
- Transfusion Medicine and Transplantation Biology, University, Zagreb, Croatia
| | | | - Bo Brink
- Department of Nephrology, University Hospital, Huddinge, Sweden
| | - Gösta Berlin
- Clinical Immunology and Transfusion Medicine, Linköping University, Linköping, Sweden
| | | | - Thomas Nilsson
- Department of Nephrology, University Hospital, Uppsala, Sweden
| | - Torsten Eich
- Blood Center, University, Uppsala, Sweden, Uppsala, Sweden
| | - Henrik Hadimeri
- Department of Nephrology, Skaraborg Hospital, Skövde, Sweden
| | | | | | - Osman Ilhan
- Department Haematology, University Hospital, Ankara, Turkey
| | - Colwyn Poole
- South African National Blood Service, Johannesburg, South Africa
| |
Collapse
|
3
|
De Silvestro G, Bagatella P, Vicarioto M, Tison T, Marson P. The Italian Sidem Registry for Apheresis: An Overview of the 2005 Statistics. Int J Artif Organs 2018; 31:354-62. [DOI: 10.1177/039139880803100413] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Data collection on apheresis activities in Italy throughout 2005 including techniques, types of blood cell separators, clinical indications and adverse effects was performed by means of a standardized questionnaire. These data provided by 83 Apheresis Units from 16 Italian regions, albeit rough, are sufficiently informative, mainly in comparison with previous surveys on these statistics (1997 and 2000). In 2005 a total number of 204,746 apheresis procedures were carried out, with a clear-cut prevalence of apheresis production (87.7%), performed by 66 out of 83 Apheresis Units (79.5). Lombardy, Veneto and Tuscany were the most active regions for therapeutic apheresis (51.1% of the total national procedures). An increasing number in extracorporeal photochemotherapy as compared to the 2000 national survey (3,386 vs. 704 procedures) is the most striking observation to emerge from the 2005 data collection on therapeutic apheresis in Italy. Adverse effects, predominantly mild ones (i.e., paresthesia due to citrate-induced hypocalcemia), occurred in 0.12% of apheresis production and 6.04 of therapeutic sessions, particularly in the course of peripheral blood stem cell collection (20.79%), as already reported in the 2000 national survey.
Collapse
Affiliation(s)
- G. De Silvestro
- Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua - Italy
| | - P. Bagatella
- Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua - Italy
- Venetian Institute of Oncology, Venice - Italy
| | - M. Vicarioto
- Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua - Italy
| | - T. Tison
- Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua - Italy
| | - P. Marson
- Apheresis Unit, Blood Transfusion Service, University Hospital of Padua, Padua - Italy
| |
Collapse
|
4
|
Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on. ATHEROSCLEROSIS SUPP 2017; 30:50-55. [PMID: 29096861 DOI: 10.1016/j.atherosclerosissup.2017.05.006] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND In recent years the Federal Joint Committee (G-BA), a paramount decision-making body of the German health care system required a reassessment of the approval of chronic lipoprotein apheresis therapy for regular reimbursement. Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology. In 2009 the working group completed the indication for lipoprotein apheresis with respect to current cardiovascular guidelines and current scientific knowledge for the registry. In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data acquired over nearly 5 years can now be reported. METHODS AND RESULTS All data were collected and analyzed during the time period 2012-2015. Over this time interval, 68 German apheresis centers collected retrospective and prospective observational data of 1.283 patients undergoing lipoprotein apheresis (LA) treatment of high LDL-cholesterol (LDL-C) levels and/or high lipoprotein(a) (Lp(a)) levels suffering from progressive cardiovascular disease (CVD). A total of 15,167 documented LA treatments were investigated. All patients treated by LA exhibited a median LDL-C reduction rate of 68.6%, and a median Lp(a) reduction rate of 70.4%. Analogue to the Pro(a)LiFe pattern, patient data were analyzed and compared with respect to the incidence rate of coronary events (MACE) 1 and 2 years before the start of LA treatment (y-2 and y-1) and prospectively one year on LA treatment (y+1). During the first year of LA treatment a MACE reduction of 97% was be observed. In the years considered, LA treatment side effects occurred at a low rate (ca. 5%) and mainly comprised puncture problems. CONCLUSIONS For the first time data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp(a) levels, progressive CVD and maximally tolerated lipid lowering medication. In addition LA treatments were found to be safe, exhibiting a low rate of side effects.
Collapse
Affiliation(s)
| | - C L Neumann
- BRAVE e Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e.V., Göttingen, Germany
| | - C Peter
- BioArtProducts GmbH (B.A.P.), Rostock, Germany; Fraunhofer Institute for Cell Therapy and Immunology IZI, Rostock Group (EXIM), Germany
| | | | - U Julius
- Department of Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany
| | - E Roeseler
- Center for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany
| | - F Heigl
- Medical Care Centre Kempten-Allgäu, Kempten, Germany
| | - P Grützmacher
- Department of Medicine II for Nephrology, Hypertension and Vascular Risks, AGAPLESION Markus Hospital, Frankfurt, Germany
| | - H Blume
- Scientific Institute for Nephrology (WiNe), Düsseldorf, Germany
| | | |
Collapse
|
5
|
Abstract
BACKGROUND Since 2005 an interdisciplinary German apheresis working group has been established by members of both German Societies of Nephrology and of Lipidologists and completed the data set for the registry according to the current guidelines and the German indication guideline for apheresis in 2009. In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 5 years now. METHODS AND RESULTS During the time period 2012-2016, 71 German apheresis centers collected retrospective and prospective observational data of 1435 patients undergoing lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from cardiovascular disease (CVD) or progressive CVD. A total of 15,527 completely documented LA treatments were entered into the database. All patients treated by LA showed a median LDL-C reduction rate of 67.5%, and a median Lp (a) reduction rate of 71.1%. Analog to the Pro(a)LiFe pattern, patient data were analyzed to the incidence rate of coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y‑1) and prospectively two years on LA treatment (y + 1 and y + 2). During two years of LA treatment a MACE reduction of 78% was observed. In the years considered, side effects of LA treatment were low (5.9%) and mainly comprised puncture problems. CONCLUSIONS The data generated by the GLAR shows that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp (a) levels, progressive CVD, and maximally tolerated lipid lowering medication. In addition, LA treatments were found to be safe with a low rate of side effects.
Collapse
|
6
|
Mann SA, McCleskey B, Marques MB, Adamski J. Establishing an institutional therapeutic apheresis registry. J Clin Apher 2016; 31:516-522. [DOI: 10.1002/jca.21443] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 12/02/2015] [Indexed: 11/12/2022]
Affiliation(s)
- Steven A. Mann
- Department of Pathology and Laboratory Medicine, Indiana University; Indianapolis Indiana
| | - Brandi McCleskey
- Department of Pathology; University of Alabama at Birmingham (UAB); Birmingham Alabama
| | - Marisa B. Marques
- Department of Pathology; University of Alabama at Birmingham (UAB); Birmingham Alabama
| | - Jill Adamski
- Department of Laboratory Medicine and Pathology; Mayo Clinic Arizona; Phoenix Arizona
| |
Collapse
|
7
|
Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Ramlow W, Blume H. First data from the German Lipoprotein Apheresis Registry (GLAR). ATHEROSCLEROSIS SUPP 2015; 18:41-4. [DOI: 10.1016/j.atherosclerosissup.2015.02.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
8
|
Establishment of a national on-line registry for apheresis in Korea. Transfus Apher Sci 2008; 38:93-100. [DOI: 10.1016/j.transci.2008.01.007] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2007] [Revised: 10/10/2007] [Accepted: 01/11/2008] [Indexed: 11/17/2022]
|